TX-FLUENCE
9.6.2021 13:02:11 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals (UNIVO), through Fluence’s ongoing partnership with REMY LTD (REMY), a leading, Israel-based horticultural lighting provider to the country’s growing agriculture industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005120/en/
Following the legalization of medical cannabis in 1993, Israel’s cannabis industry has flourished through in-depth research into efficient production and cultivation processes. With nearly 30 cultivators actively producing medical cannabis and dozens in planning stages, Israel is poised to meet and exceed demand for the estimated 100,000 medical cannabis users throughout the country. As legislation to legalize recreational cannabis use is evaluated, experts predict the industry will maintain its exponential growth trajectory.
“The rapid growth of the medical cannabis industry in Israel is a clear indicator of the recreational market’s potential,” said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. “To maintain the industry’s pace, cultivators must examine and invest in highly efficient production methods that yield consistent, high-quality cannabis products. Lighting plays one of the most crucial roles in that production process.”
Optimal lighting strategies for every phase of the cultivation value chain
Whether seed and variety breeding, cloning and growing plants, or the final cultivation of dense and full buds, each phase of the cannabis value chain requires optimized, curated lighting conditions. Fluence not only offers the industry’s leading LED lighting solutions, but provides evidence-based best practices to identify, implement and maintain the optimal lighting strategy at each phase of cannabis growth. Fluence’s research-backed cultivation methods supported by its team of horticulture specialists enable cannabis cultivators to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.
REMY echoes Fluence’s cultivation philosophy and approach. Through their partnership, Fluence and REMY are serving Israel’s most innovative cultivators. Springs Valley Cannabis, located in Northern Israel, relies on Fluence’s LED technology in its large-scale, high-end indoor growing facility to ensure superior cannabis flowering within the company’s first cultivation environment.
“Lighting has a major effect on our high-end indoor farm's success,” said Yair Shaked, CEO at Springs Valley Cannabis. “We searched for a lighting partner that would support us and add value for the long run—that's why we chose to work with REMY and Fluence.”
UNIVO, a vertically integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, leverages Fluence’s solutions in different stages of the growth cycle, including nursery, vegetative, flowering, mother stock, and research and development, where UNIVO clones and grows cannabis plants.
“Amit farm by UNIVO is one of the most sophisticated and technological farms in the Israeli cannabis industry, and after carefully reviewing the market, we decided to cooperate with Fluence to achieve the best premium cannabis flowers,” added Golan Bitton, CEO at UNIVO.
Continuous investment in new knowledge
“Amid Israel’s revered, dynamic high-tech industry, Fluence’s LED lighting technology is recognized as truly innovative. To maintain that position, we continuously invest in new knowledge and develop new techniques to best serve the world’s cultivators,” Bongartz added.
Fluence works closely with leading research institutions such as Wageningen University & Research to uncover new cultivation strategies and explore the influence of various light spectra on cannabis growth and development. Fluence’s collaborative research insights inform product innovations and provide growers with effective best practices to optimize plant growth.
“The job doesn’t stop when the light fixtures have been installed,” says Jörg Meyer-Brenken, Fluence’s lead account manager for cannabis in EMEA. “On the contrary, that’s when it starts and that’s where the Fluence and REMY teams add extraordinary value. REMY is a true, reliable partner. Their team combines deep lighting knowledge with years of experience in Israeli agriculture and horticulture, making REMY an ideal partner to help us reach a prominent position in this fast-growing market.”
“The end result for the cultivator is an agronomic lighting fixture, but the path to reach the optimal lighting strategy is driven by years of research and practical knowledge,” said Elad Toby, founder, CTO and chief business development officer for REMY. “There is huge opportunity in bringing Fluence’s groundbreaking knowledge to the Israeli medical cannabis market.”
For more information about Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, supervision and quality assurance of large-scale lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its showroom and headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom